The Pharmacy Times® Gastrointestinal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur in digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus, and biliary system.
November 17th 2023
The approval makes pembrolizumab the first-line treatment for individuals with this cancer.
Preventing and Managing Controlled Substance Diversion Across Health Care Settings
2.0 Credits / Law
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Trial Results Demonstrate Significant Overall Survival With Zanidatamab in Adenocarcinoma
January 25th 2023In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.
Read More
Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More
Three Major Studies Alter the Practice of Treating Gastroesophageal Carcinomas
April 12th 2021A presentation at the Community Oncology Alliance 2021 Virtual Conference focused on the latest developments in gastrointestinal oncology and how the field of gastroesophageal cancer is responding to 3 major, practice-changing trials.
Read More
Plethora of Clinical Trials Explore Gastric Cancer Treatments
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
Read More
FDA Gives Fast Track Designation for Gastric, Gastroesophageal Junction Adenocarcinoma Treatment
September 25th 2020The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.
Read More